Extracellular loop 2 of the adenosine A1 receptor has a key role in orthosteric ligand affinity and agonist efficacy

Molecular Pharmacology

Volumn 90, Issue 6, 2016, Pages 703-714

  Nguyen, Anh T N ^a   Baltos, Jo Anne ^a   Thomas, Trayder ^a   Nguyen, Toan D ^a   Muñoz, Laura López ^a   Gregory, Karen J ^a   White, Paul J ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a   May, Lauren T ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE; ALANINE; CYCLIC AMP; LIGAND; MUTANT PROTEIN; XANTHINE DERIVATIVE;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DISULFIDE BOND; DRUG BINDING SITE; DRUG RECEPTOR BINDING; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTAGENESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; AMINO ACID SUBSTITUTION; ANIMAL; BINDING SITE; CELL MEMBRANE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HAMSTER; HUMAN; METABOLISM; PROTEIN SECONDARY STRUCTURE; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ADENOSINE; ADENOSINE A1 RECEPTOR AGONISTS; ALANINE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; HUMANS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, ADENOSINE A1; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 84996549586     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.116.105007     Document Type: Article

References (63)

1. Abagyan R and Kufareva I (2009) The flexible pocketome engine for structural chemogenomics. Methods Mol Biol 575:249-279.
2. An J, Totrov M, and Abagyan R (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 4:752-761.
3. Avlani VA, Gregory KJ, Morton C.J., Parker MW, Sexton PM, and Christopoulos A (2007) Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem 282: 25677-25686.
4. Ballesteros J and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G-protein-coupled receptors. Methods Neurosci 25:366-428.
5. Baltos JA, Gregory KJ, White P.J., Sexton PM, Christopoulos A, and May LT (2016) Quantification of adenosine A(1) receptor biased agonism: implications for drug discovery. Biochem Pharmacol 99:101-112.
6. Banères J.L., Mesnier D, Martin A., Joubert L, Dumuis A, and Bockaert J (2005) Molecular characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy. J Biol Chem 280:20253-20260.
7. Barbhaiya H, McClain R, Ijzerman A., and Rivkees SA (1996) Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol Pharmacol 50:1635-1642.
8. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Congreve M, Andrews SP, Doré AS, Hollenstein K, Hurrell E, Langmead CJ, Mason JS, Ng IW, Tehan B, Zhukov A, et al. (2012) Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem 55: 1898-1903.
11. Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, Magnani F, et al. (2011) Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19: 1283-1293.
12. Dror RO, Pan AC, Arlow D.H., Borhani DW, Maragakis P, Shan Y, Xu H., and Shaw DE (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci USA 108:13118-13123.
13. Duan Y, Wu C, Chowdhury S., Lee MC, Xiong G, Zhang W, Yang R., Cieplak P, Luo R, Lee T., et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. JComput Chem 24:1999-2012.
14. Duong HT, Gao ZG, and Jacobson KA (2005) Nucleoside modification and concerted mutagenesis of the human A3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop. Nucleosides Nucleotides Nucleic Acids 24:1507-1517.
15. Essmann U, Perera L, Berkowitz M.L., Darden T., Lee H, and Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577-8593.
16. Eswar N, Webb B, Marti-Renom MA, Madhusudhan M.S., Eramian D., Shen MY, Pieper U, and Sali A (2007) Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci Chapter 2: Unit 2.9.
17. Fredholm BB, IJzerman AP, Jacobson K.A., Klotz KN, and Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
18. Gao ZG, Chen A, Barak D., Kim SK, Müller CE, and Jacobson KA (2002) Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem 277: 19056-19063.
19. 2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285: 7459-7474.
20. Gregory KJ, Sexton PM, Tobin A.B., and Christopoulos A (2012) Stimulus bias provides evidence for conformational constraints in the structure of a G proteincoupled receptor. J Biol Chem 287:37066-37077.
21. Hess S (2001) Recent advances in adenosine receptor antagonist research. Expert Opin Ther Pat 11:1533-1561.
22. Hino T, Arakawa T, Iwanari H., Yurugi-Kobayashi T, Ikeda-Suno C, Nakada-Nakura Y, Kusano-Arai O, Weyand S., Shimamura T, Nomura N, et al (2012) G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482: 237-240.
23. Howl J and Wheatley M (1996) Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors. Biochem J 317:577-582.
24. Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38, 27-28.
25. 2A adenosine receptor bound to an antagonist. Science 322:1211-1217.
26. Jacobson KA and Gao Z-G (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264.
27. 1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol 151:1025-1032.
28. 2a adenosine receptor are required for ligand recognition. Mol Pharmacol 49:683-691.
29. Kobilka BK (2007) G protein coupled receptor structure and activation. Biochim Biophys Acta 1768:794-807.
30. Koole C, Wootten D, Simms J., Miller LJ, Christopoulos A, and Sexton PM (2012) Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem 287: 3642-3658.
31. Leach K, Davey AE, Felder C.C., Sexton PM, and Christopoulos A (2011) The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. Mol Pharmacol 79:855-865.
32. 2A receptor. Mol Pharmacol 87: 907-915.
33. 2A receptor structures reveal common features of GPCR activation. Nature 474:521-525.
34. Liu W, Chun E, Thompson A.A., Chubukov P., Xu F, Katritch V, Han G.W., Roth CB, Heitman LH, IJzerman AP, et al (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-236.
35. MacKerell AD, Bashford D, Bellott M., Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J., Guo H, Ha S, et al (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586-3616.
36. MacKerell AD, Jr, Feig M, and Brooks CL, 3rd (2004) Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 25:1400-1415.
37. Martinelli A and Tuccinardi T (2008) Molecular modeling of adenosine receptors: new results and trends. Med Res Rev 28:247-277.
38. 2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476.
39. Müller CE and Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Act 1808:1290-1308.
40. 3 adenosine receptors. J Biol Chem 269:24692-24698.
41. Palmer TM and Stiles GL (1995) Adenosine receptors. Neuropharmacology 34: 683-694.
42. Phillips JC, Braun R, Wang W., Gumbart J, Tajkhorshid E, Villa E., Chipot C, Skeel RD, Kalé L, and Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802.
43. 1 adenosine receptor. J Biol Chem 274:3617-3621.
44. 2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics. MedChemComm 6: 1081-1085.
45. 3 muscarinic acetylcholine receptor activation. J Biol Chem 282:7385-7396.
46. 2B receptor: role in ligand binding and receptor function. Biochem Pharmacol 82:389-399.
47. Scholl DJ and Wells JN (2000) Serine and alanine mutagenesis of the nine native cysteine residues of the human A(1) adenosine receptor. Biochem Pharmacol 60: 1647-1654.
48. 2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 101:440-445.
49. Shi L, Liapakis G, Xu R., Guarnieri F, Ballesteros JA, and Javitch JA (2002) Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 277:40989-40996.
50. Shonberg J, Herenbrink CK, López L, Christopoulos A., Scammells PJ, Capuano B, and Lane JR (2013) A structure-activity analysis of biased agonism at the dopamine D2 receptor. J Med Chem 56:9199-9221.
51. Sromek SM and Harden TK (1998) Agonist-induced internalization of the P2Y2 receptor. Mol Pharmacol 54:485-494.
52. 3 receptor on Gi protein-dependent signalling and Gi-independent receptor internalization. Br J Pharmacol 171:3827-3844.
53. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F., and Higgins DG (1997) The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882.
54. Townsend-Nicholson A and Schofield PR (1994) A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J Biol Chem 269:2373-2376.
55. Unal H, Jagannathan R, Bhat M.B., and Karnik SS (2010) Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem 285:16341-16350.
56. Valant C, May LT, Aurelio L, Chuo C.H., White PJ, Baltos JA, Sexton PM, Scammells P.J., and Christopoulos A (2014) Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl Acad Sci USA 111:4614-4619.
57. Vanommeslaeghe K, Hatcher E, Acharya C., Kundu S, Zhong S, Shim J., Darian E, Guvench O, Lopes P., Vorobyov I, et al. (2010) CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 31:671-690.
58. Vecchio EA, Tan CY, Gregory K.J., Christopoulos A., White PJ, and May LT (2016) Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation. J Pharmacol Exp Ther 357:36-44.
59. Wheatley M, Wootten D, Conner M.T., Simms J., Kendrick R, Logan RT, Poyner D.R., and Barwell J (2012) Lifting the lid on GPCRs: the role of extracellular loops. Br J Pharmacol 165:1688-1703.
60. Wifling D, Bernhardt G, Dove S., and Buschauer A (2015) The extracellular loop 2 (ECL2) of the human histamine H4 receptor substantially contributes to ligand binding and constitutive activity. PLoS One 10:e0117185.
61. Xu F, Wu H, Katritch V., Han GW, Jacobson KA, Gao ZG, Cherezov V, and Stevens RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-327.
62. Yaar R, Jones MR, Chen J.F., and Ravid K (2005) Animal models for the study of adenosine receptor function. J Cell Physiol 202:9-20.
63. Yu W, He X, Vanommeslaeghe K., and MacKerell AD, Jr (2012) Extension of the CHARMM General Force Field to sulfonyl-containing compounds and its utility in biomolecular simulations. J Comput Chem 33:2451-2468.